Regulus Therapeutics Inc. (RGLS)
RGLS moved a median of +0.26% 30 minutes after news, and +0.26% by the close. How RGLS actually reacts to news — the realized, point-in-time move the market made, measured across 201 labeled events over the last three years with zero look-ahead.
RGLS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.13% | 53% | 135 |
| 30-min | +0.26% | 55% | 148 |
| 60-min | +0.26% | 55% | 148 |
| to close | +0.26% | 59% | 148 |
| Middle 50% of RGLS reactions | -0.90% to +1.35% |
|---|---|
| Median reaction (30-min) | +0.26% |
| Measured reactions | 201 |
Half of all Regulus Therapeutics Inc. news events land between -0.90% and +1.35% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RGLS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 11 | +0.25% | 55% | +0.26% |
| Coverage initiations | 35 | 0.00% | 54% | -0.22% |
| Rating reiterations | 34 | -0.33% | 32% | +1.03% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how RGLS ranks against every other measured name →
That’s how RGLS usually reacts — get an email when it moves on news →Email me when RGLS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RGLS's baseline. Nothing else.
Recent RGLS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Regulus Therapeutics | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT Regulus Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K Regulus Therapeutics For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Regulus Therapeutics | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS Regulus Therapeutics | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 10-Q Regulus Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.15% | +0.51% | |
| Form 8-K Regulus Therapeutics For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +1.15% | +0.51% | |
| Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates | Press release | PR Newswire | +1.15% | +0.51% | |
| Form 10-K/A Regulus Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.13% | +0.26% | |
| Form 8-K Regulus Therapeutics For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -1.38% | -0.25% | |
| Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG | Press release | PR Newswire | -1.38% | -0.25% | |
| RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders | Press release | Business Wire | -1.38% | -0.25% | |
| Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit | Press release | PR Newswire | +1.46% | +14.62% | |
| Form 8-K Regulus Therapeutics For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +1.06% | +5.63% | |
| Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Press release | PR Newswire | +1.06% | +5.63% | |
| Form 10-K Regulus Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.73% | +8.03% | |
| Form 8-K Regulus Therapeutics For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | +0.73% | +8.03% | |
| Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates | Press release | PR Newswire | +0.73% | +8.03% | |
| Form 8-K Regulus Therapeutics For: Feb 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.27% | |
| Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference | Press release | PR Newswire | -1.61% | +8.87% | |
| Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference | Press release | PR Newswire | +4.78% | -1.47% | |
| Form S-8 Regulus Therapeutics | SEC filing · Form S-8 | SEC EDGAR | +7.41% | +7.53% | |
| Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) | Press release | PR Newswire | -2.83% | -8.49% | |
| Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences | Press release | PR Newswire | -1.95% | -0.65% | |
| Form 10-Q Regulus Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.41% | -0.68% | |
| Form 8-K Regulus Therapeutics For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | -0.68% | |
| Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates | Press release | PR Newswire | +0.41% | -0.68% | |
| Form 8-K Regulus Therapeutics For: Oct 22 | SEC filing · Form 8-K | SEC EDGAR | +2.19% | +1.41% | |
| Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Press release | PR Newswire | -3.47% | -10.40% | |
| Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences | Press release | PR Newswire | +0.00% | -8.29% | |
| Form 10-Q Regulus Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.77% | -5.13% | |
| Form 8-K Regulus Therapeutics For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | -5.77% | -5.13% | |
| Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates | Press release | PR Newswire | -5.77% | -5.13% | |
| Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference | Press release | PR Newswire | -1.33% | +1.33% | |
| Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences | Press release | PR Newswire | -3.80% | -8.70% | |
| Form 8-K Regulus Therapeutics For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +10.68% | -0.48% | |
| Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Press release | PR Newswire | +10.68% | -0.48% | |
| Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes | Press release | PR Newswire | +4.04% | -0.90% | |
| Form S-8 Regulus Therapeutics | SEC filing · Form S-8 | SEC EDGAR | +0.51% | -4.54% | |
| Form 8-K Regulus Therapeutics For: May 16 | SEC filing · Form 8-K | SEC EDGAR | -2.00% | +0.50% | |
| Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer | Press release | PR Newswire | +0.00% | -0.50% | |
| Form 10-Q Regulus Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +6.57% | +3.76% | |
| Form 8-K Regulus Therapeutics For: May 09 | SEC filing · Form 8-K | SEC EDGAR | +6.57% | +3.76% | |
| Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates | Press release | PR Newswire | +6.57% | +3.76% | |
| Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Press release | PR Newswire | +0.37% | -10.33% | |
| Form DEFA14A Regulus Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +9.13% | |
| Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series | Press release | PR Newswire | +0.00% | -8.37% | |
| Form EFFECT Regulus Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | +1.91% | +5.26% | |
| Form ARS Regulus Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.91% | +5.26% | |
| Form DEF 14A Regulus Therapeutics For: May 16 | SEC filing · Form DEF | SEC EDGAR | +1.91% | +5.26% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RGLS section they belong to.
Where else RGLS is measured.
RGLS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Immuron Limited - American Depositary Shares (IMRN) | 202 | -0.21% | 29% |
| InfuSystems Holdings, Inc. (INFU) | 202 | 0.00% | 50% |
| Daxor Corporation - Closed End Fund (DXR) | 200 | 0.00% | 50% |
| The Joint Corp. (JYNT) | 200 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Regulus Therapeutics Inc.'s median reaction calculated?
Every labeled RGLS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 201 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of RGLS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RGLS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.